ADMA Biologics (NASDAQ:ADMA) Issues Earnings Results, Hits Expectations

ADMA Biologics (NASDAQ:ADMA) issued its earnings results on Wednesday. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.16, FiscalAI reports. ADMA Biologics had a net margin of 32.43% and a return on equity of 39.98%. The company had revenue of $124.39 million for the quarter, compared to analysts’ expectations of $125.34 million.

Here are the key takeaways from ADMA Biologics’ conference call:

• ASCENIV momentum accelerated: Second-quarter revenue rose 24% year over year to $102.9 million, with June showing the strongest sequential end-user utilization growth since the first half of 2024. Management attributed the trend to increased physician adoption, new patient starts, broader payer engagement, and supporting real-world evidence.
• Profitability and cash generation improved: Revenue increased 2% year over year to $124.4 million, while gross margin expanded to 69% from 55% and adjusted EBITDA rose 22% to $61.8 million, supported by ASCENIV mix and manufacturing efficiencies.
• BIVIGAM remains under pressure: Although demand and revenue improved sequentially as market conditions stabilized, management still expects BIVIGAM revenue to decline approximately 40%–50% from 2025 levels amid excess standard immunoglobulin supply, discounting, and competitive pressures.
• 2026 guidance was reiterated: ADMA continues to forecast revenue of $530 million–$560 million, adjusted EBITDA of $265 million–$300 million, and adjusted net income of $170 million–$200 million, while stating it remains confident in meeting or exceeding those expectations.
• Capital allocation and pipeline progress continued: The company repurchased approximately 7.1 million shares in the quarter and remains on track for at least $200 million of 2026 buybacks. SG-001 is advancing toward conformance lot production in the second half of 2026 and a planned FDA pre-IND meeting package submission by year-end, with management estimating a potential $300 million–$500 million annual opportunity if approved.

ADMA Biologics Stock Performance

Shares of NASDAQ ADMA traded up $0.35 during mid-day trading on Wednesday, hitting $9.26. The stock had a trading volume of 3,784,547 shares, compared to its average volume of 4,667,146. The firm has a market cap of $2.15 billion, a PE ratio of 13.62 and a beta of 0.74. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.93 and a current ratio of 6.95. The company has a 50 day moving average of $8.52 and a two-hundred day moving average of $11.43. ADMA Biologics has a twelve month low of $7.21 and a twelve month high of $20.46.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Wall Street Zen cut ADMA Biologics from a “buy” rating to a “hold” rating in a research report on Monday, May 4th. Canaccord Genuity Group decreased their price objective on ADMA Biologics from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a research report on Thursday, June 18th. Raymond James Financial assumed coverage on ADMA Biologics in a research note on Wednesday, June 10th. They issued an “outperform” rating and a $21.00 target price on the stock. Finally, Zacks Research upgraded shares of ADMA Biologics from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Three investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $18.67.

Insiders Place Their Bets

In other news, Director Jerrold B. Grossman acquired 12,500 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were acquired at an average cost of $8.01 per share, with a total value of $100,125.00. Following the completion of the acquisition, the director owned 513,884 shares of the company’s stock, valued at approximately $4,116,210.84. This trade represents a 2.49% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 3.90% of the company’s stock.

Institutional Investors Weigh In On ADMA Biologics

A number of large investors have recently bought and sold shares of the company. Royal Bank of Canada raised its position in ADMA Biologics by 112.7% during the 1st quarter. Royal Bank of Canada now owns 95,885 shares of the biotechnology company’s stock worth $1,903,000 after buying an additional 50,801 shares during the last quarter. Ashton Thomas Private Wealth LLC purchased a new stake in shares of ADMA Biologics in the 1st quarter valued at $217,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of ADMA Biologics by 59.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 816,590 shares of the biotechnology company’s stock worth $16,201,000 after acquiring an additional 305,064 shares during the period. Norges Bank acquired a new stake in shares of ADMA Biologics in the second quarter worth $549,000. Finally, EverSource Wealth Advisors LLC raised its holdings in shares of ADMA Biologics by 385.8% during the second quarter. EverSource Wealth Advisors LLC now owns 2,745 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 2,180 shares during the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

ADMA Biologics News Roundup

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: Strong profitability and ASCENIV growth: Second-quarter revenue rose 2% year over year to $124.4 million, while GAAP net income increased 11% to $37.8 million. Adjusted EBITDA grew 22% to $61.8 million, and ASCENIV revenue climbed 24% to $102.9 million. ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Per-share results met expectations: ADMA reported quarterly EPS of $0.16, in line with consensus estimates. The company also cited stabilized BIVIGAM utilization, sequential improvement in demand, and a strong balance sheet supporting continued execution. ADMA Biologics Earnings Results
• Positive Sentiment: Full-year revenue outlook was maintained: ADMA issued FY 2026 revenue guidance of $530 million to $560 million, above the current consensus midpoint of approximately $535 million. The company also reiterated its broader FY 2026 financial guidance. ADMA FY 2026 Guidance

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.